



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(s): BARTHOLOMAUS et al.  
SERIAL NO.: 10/718,112 ART UNIT:  
FILING DATE: 11/20/03 EXAMINER:  
TITLE: ABUSE-PROOFED DOSAGE FORM  
ATTORNEY  
DOCKET NO.: 785-011574-US (PAR)

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
(37 C.F.R. §1.97(b)(3))

Sir:

This information disclosure statement is being filed before the mailing of a first Office Action on the merits.

The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application. Applicants' Attorney is aware of the following references:

- US 4,070,494
- WO 95/20947
- WO 03/015531
- US 2003/0064099
- US 4,765,989
- US 4,612,008
- US 4,783,337
- WO 98/20073
- DE 197 53 534
- DE 198 00 698
- EP 0 820 698
- DE 198 22 979

DE 43 09 528  
EP 0 980 894  
EP 0 780 369  
EP 0 693 475

Pharmazeutische Biologie Drogen und ihre Inhaltsstoffe  
(pp. 82-92)

Coated Pharmaceutical Dosage Forms (pp. 1-10)


2.9 Methoden der pharmazeutischen Technologie (pp. 143-144)

Copies of these references are enclosed together with a Form PTO-1449.

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

The Commissioner is hereby authorized to charge payment for any fees associated with this communication or credit any over payment to Deposit Account No. 16-1350.

Respectfully submitted,

  
\_\_\_\_\_  
Geza S. Ziegler, Jr.  
Reg. No. 44,004

24 Feb 2004  
\_\_\_\_\_  
Date

PERMAN & GREEN, LLP  
425 Post Road  
Fairfield, CT 068424  
Customer No. 2512

**INFORMATION DISCLOSURE****CITATION FORM FOR  
PATENT APPLICATION****FORM PTO-1449**

(Substitute)

Docket No.: 785-011574-US (PAR)

Serial No.: 10/718,112

Applicant(s): BARTHOLOMAUS et al.

Filing Date: 11/20/03

Group:

**U.S. PATENTS**

Patent Number	Issue Date	Name	Class	Sub-class	Filing date
4,070,494	1/24/78	Hoffmeister et al.	424	2	
4,612,008	9/16/86	Wong et al.	604	892	
4,765,989	8/23/88	Wong et al.	424	473	
4,783,337	11/8/88	Wong et al.	424	468	

**U.S. PATENT PUBLICATIONS**

Initials	Publication No.	Pub. Date	Name	Class	Sub-class	Filing Date
	2003/0064099	4/3/03	Oshlack et al.	424	465	

**FOREIGN PATENT DOCUMENTS**

Initials	Document Number	Date	Country	Name	Translation? Yes/No/n/a
	WO 95/20947	10.08.95	PCT	Rhonepoulenc Rorer Limited	N/A
	WO 03/015531	27.02.03	PCT	Gruber, Thomas	N/A
	WO 98/20073	14.05.98	PCT	Novamont S.P.A.	N/A
	DE 19753534	03.12.97	Germany	Bayer AG	No
	DE 19800698	10.01.98	Germany	Bayer AG	No
	EP 0820698	28.01.98	EPO	Wolff Walsrode AG	No
	DE 19822979	25.05.98	Germany	Kalle Nalo GmbH & Co.	No
	DE 4309528	24.03.93	Germany	Metzger, Wolfgang	No
	EP 0980894	23.02.00	Germany	Mitsui Chemicals, Inc.	N/A
	EP 0693475	24.01.96	EPO	Grunenthal GmbH	No
	EP 0780369	25.06.97	EPO	Grunenthal GmbH	No

**OTHER DOCUMENTS (Title, Author, Date, Pages, Etc., if known)**

	Pharmazeutische Biologie Drogen und ihre Inhaltsstoffe, Professor Dr. Hildebert Wagner, Munchen, 1982, Pages 82-92.
	2.9 Methoden der pharmazeutischen Technologie, pages 143-144.
	Coated Pharmaceutical Dosage Forms, K.H. Bauer, et al., CRC Press, 1998, pages 1-10.

Examiner's Signature:

Date Considered:

Initial if reference was considered, whether or not citation is in conformance with MPEP. Mark through citation if not considered.

Include a copy of this citation form with your next correspondence to the Applicant(s).